KDR and hepatocellular carcinoma: Similarly, ramucirumab is a monoclonal antibody inhibitor targeting VEGFR2 that is approved for the treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma, NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma (HCC) [84,85,86,87].